Management of hepatitis C virus infection in the Asia-Pacific region: an update

详细信息    查看全文

• 作者：Prof Seng Gee Lim ; FRCP^a ; ^{mdclimsg@nus.edu.sg} ; Alessio Aghemo ; PhD^b ; Prof Pei-Jer Chen ; PhD^c ; Yock Young Dan ; PhD^a ; Prof Edward Gane ; FRACP^d ; Prof Rino Gani ; PhD^e ; Prof Robert G Gish ; MD^f ; Richard Guan ; FRCP^g ; Prof Ji Dong Jia ; PhD^h ; Kieron Lim ; MRCP^a ; Teerha Piratvisuth ; MDⁱ ; Samir Shah ; MD^j ; Prof Mitchell L Shiffman ; MD^k ; Frank Tacke ; MD^l ; Soek Siam Tan ; MRCP^m ; Tawesak Tanwandee ; MDⁿ ; Prof Khin Maung Win ; MD^o ; Prof Cihan Yurdaydin ; MD^p
• 刊名：The Lancet Gastroenterology & Hepatology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：2
• 期：1
• 页码：52-62
• 全文大小：304 K
• 卷排序：2

文摘

The Asia-Pacific region has disparate hepatitis C virus (HCV) epidemiology, with prevalence ranging from 0·1% to 4·7%, and a unique genotype distribution. Genotype 1b dominates in east Asia, whereas in south Asia and southeast Asia genotype 3 dominates, and in Indochina (Vietnam, Cambodia, and Laos), genotype 6 is most common. Often, availability of all-oral direct-acting antivirals (DAAs) is delayed because of differing regulatory requirements. Ideally, for genotype 1 infections, sofosbuvir plus ledipasvir, sofosbuvir plus daclatasvir, or ombitasvir, paritaprevir, and ritonavir plus dasabuvir are suitable. Asunaprevir plus daclatasvir is appropriate for compensated genotype 1b HCV if baseline NS5A mutations are absent. For genotype 3 infections, sofosbuvir plus daclatasvir for 24 weeks or sofosbuvir, daclatasvir, and ribavirin for 12 weeks are the optimal oral therapies, particularly for patients with cirrhosis and those who are treatment experienced, whereas sofosbuvir, pegylated interferon, and ribavirin for 12 weeks is an alternative regimen. For genotype 6, sofosbuvir plus pegylated interferon and ribavirin, sofosbuvir plus ledipasvir, or sofosbuvir plus ribavirin for 12 weeks are all suitable. Pegylated interferon plus ribavirin has been replaced by sofosbuvir plus pegylated interferon and ribavirin, and all-oral therapies where available, but cost and affordability remain a major issue because of the absence of universal health coverage. Few patients have been treated because of multiple barriers to accessing care. HCV in the Asia-Pacific region is challenging because of the disparate epidemiology, poor access to all-oral therapy because of availability, cost, or regulatory licensing. Until these problems are addressed, the burden of disease is likely to remain high.